Home › Rating Schedule › Hemic and Lymphatic Systems
Diagnostic Code 7718: Essential thrombocythemia and primary myelofibrosis
Hemic and Lymphatic Systems · 38 CFR §4.117 · All codes in this system
| Evaluation criteria | Rating |
|---|---|
| Requiring either continuous myelosuppressive therapy, or, for six months following hospital admission for any of the following treatments: peripheral blood or bone marrow stem cell transplant, or chemotherapy, or interferon treatment | 100% |
| Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count <500 × 109/L | 70% |
| Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count of 200,000-400,000, or white blood cell (WBC) count of 4,000-10,000 | 30% |
| Asymptomatic | 0% |
| Note (1): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703. | |
| Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant; or during the period of treatment with chemotherapy (including myelosuppressants) or interferon treatment. Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. | |
Use this rating
Open the combined ratings calculator with this percentage already entered, then add your other rated conditions:
100% in the calculator 70% in the calculator 30% in the calculator 0% in the calculator
Source: eCFR Title 38, 38 CFR §4.117, current as of 2026-11-05. Criteria text is the regulatory text, reproduced verbatim for reference; it is not legal advice.